Document Detail


Prevention of a first myocardial infarction.
MedLine Citation:
PMID:  11304891     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Coronary heart disease is the leading cause of morbidity and mortality in men and women in the Western world. We now have significant evidence that prevention of the first coronary event using lifestyle and pharmacologic therapies is paramount. Events are caused by inflamed arteries leading to rupture of atherosclerotic plaques that induce potentially occlusive thrombi. Analysis of event reduction trials has revealed that LDL-C lowering is only one part of the therapy needed to stabilize plaque. HMG-Co-A-reductase inhibitors, fibrates, and statins all have differing mechanisms of action that provide not only lipid but also inflammatory, rheologic, and coagulation benefits. Concentration and sizes of lipoprotein subfractions have emerged as important new tools with small dense LDL particles having more atherogenicity, which has led to an increasing use of aggressive combination therapy for prevention of first myocardial infarction. Proper use of lipid-lowering therapies requires knowledge of drug metabolism drug-drug interactions.
Authors:
T D Dayspring
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  41     ISSN:  0091-2700     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  2001 Apr 
Date Detail:
Created Date:  2001-04-17     Completed Date:  2001-09-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  359-67     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Markers / analysis
Cholesterol, LDL / analysis
Drug Therapy, Combination
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology,  therapeutic use
Hypercholesterolemia / prevention & control*,  therapy
Inflammation / drug therapy
Myocardial Infarction / etiology,  prevention & control*,  therapy
Risk Factors
Thrombosis / prevention & control
Vasodilation / drug effects
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New diagnostic criteria for the neuropsychiatric form of systemic lupus erythematosus
Next Document:  Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need f...